Trial Profile
A Retrospective study to evaluate the efficacy of Nivolumab associated with the T790M status in patients with EGFR mutation(+) Non-Small Cell Lung Cancer who are resistant to EGFR-TKI Treatment
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 21 Apr 2017
Price :
$35
*
At a glance
- Drugs Nivolumab (Primary)
- Indications Non-small cell lung cancer
- Focus Pharmacodynamics; Therapeutic Use
- 21 Apr 2017 New trial record
- 12 Apr 2017 Results published in the Annals of Oncology